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Trent Development and Evaluation Committee 
 
The purpose of the Trent Development and Evaluation Committee is to help health authority and 
other purchasers within the Trent Region by commenting on expert reports which evaluate changes in 
health service provision. The Committee is comprised of members appointed on the basis of their 
individual knowledge and expertise, and includes non-clinically qualified scientists and lay members. 
It is chaired by Professor Sir David Hull. 
 
The committee recommends, on the basis of appropriate evidence, priorities for: 
x the direct development of innovative services on a pilot basis; 
x service developments to be secured by health authorities. 
 
The statement that follows was produced by the Development and Evaluation Committee at its 
meeting on 22 July 1997 at which this Guidance Note for Purchasers (in a draft form) was 
considered. 
 
THE USE OF RILUZOLE IN THE TREATMENT OF AMYOTROPHIC 
LATERAL SCLEROSIS (MOTOR NEURONE DISEASE)  
 
AUTHORS: Chilcott J, Golightly P, Jefferson D, McCabe C and Walters S. Sheffield: Trent Institute 
for Health Services Research, Universities of Leicester, Nottingham and Sheffield, 1997. (Guidance 
Note for Purchasers: 97/03) 
 
EXPERT ADVISOR TO TRENT DEC: Mr Chilcott, Senior Analyst from ScHARR. 
 
SUMMARY: 
Amyotrophic lateral sclerosis (ALS), a form of motor neurone disease, is a progressive and fatal 
neurodegenerative disorder with a very poor prognosis; from the onset of symptoms, five year 
survival is 5-15%, with a median survival time of about three years. Prior to the introduction of 
riluzole, only symptomatic and supportive care has been available. 
 
Two randomised controlled trials show that treatment with riluzole for up to 18 months significantly 
increases survival in ALS. Riluzole retards disease progression to a limited extent, but does not 
appear to arrest the disease and, on current evidence, it provides no other subjective or objective 
improvements. Quality of life studies have not been undertaken. 
 
However, the short duration of the two studies and the adjustment for prognostic factors means that 
there is a high level of uncertainty in the benefits achieved from the use of riluzole. The cost per life 
year gained over 18 months of treatment obtained from a direct analysis of the trial data as published, 
is approximately £50,000, with a lower estimate of £22,000 and worst case of no benefit observed. 
When results are adjusted for prognostic factors and modelled over 10 years, the mid-range estimate 
is £27,600 per life year gained. 
 
The cost of treatment is about £3,700 per patient year. The total annual cost for a  typical district of 
500,000 population providing riluzole therapy to all ALS patients is approximately £99,000. This, 
however, represents a maximum as not all patients would be eligible for, or would request, treatment. 
 
DECISION: The Committee felt unable to support the funding of Riluzole on either an 
unlimited or limited basis because of the uncertainties in the interpretation and analysis of trial 
evidence on survival, the lack of quality of life information, the limited benefit that is actually 
claimed, and the high cost-effectiveness ratio even when derived from adjusted trial data. 
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FOREWORD 
 
A network exists in the Trent Region where purchasers can share research knowledge 
about the effectiveness and cost-effectiveness of acute service interventions and determine 
collectively their purchasing policy. 
 
ScHARR, which houses the Sheffield Unit of the Trent Institute for Health Services 
Research, facilitates a Working Group on Acute Purchasing. A list of interventions for 
consideration is recommended by the purchasing authorities in Trent and approved by the 
Purchasing Authorities Chief Executives (PACE) and the Trent Development and Evaluation 
Committee (DEC). A public health consultant from a purchasing authority leads on each 
topic and is assisted by a support team from ScHARR, led by Dr Nick Payne, Senior 
Lecturer in Public Health Medicine, which provides help including literature searching, health 
economics and modelling. A seminar is then led by the consultant on the particular 
intervention where purchasers and provider clinicians consider research evidence and agree 
provisional recommendations on purchasing policy. The guidance emanating from the 
seminars is reflected in this series of Guidance Notes which have been ratified by the Trent 
DEC which is chaired by Professor Sir David Hull. 
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working with three units in other regions (The Wessex Institute for Health Research and 
Development, The Scottish Health Purchasing Information Centre (SHPIC) and The 
Birmingham University Institute for Public and Environmental Health) to share this work on 
reviewing the effectiveness and cost-effectiveness of clinical interventions. This group, 
InterDEC, will share this work, avoid duplication and improve the peer reviewing and quality 
control of these reports. 
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EXECUTIVE SUMMARY 
 
 
x Amyotrophic lateral sclerosis (ALS), a form of motor neurone disease, is a progressive 
and fatal neurodegenerative disorder with a very poor prognosis; from onset of symptoms 
five year survival is 5-15%, with a median survival time of about three years. Prior to the 
introduction of riluzole, only symptomatic and supportive care has been available. 
  
x Riluzole ('Rilutek', Rhone-Poulenc Rorer) is a new drug licensed throughout the 
European Union and in the United States for use to extend life or the time to mechanical 
ventilation in patients with ALS.  It was marketed in the UK in August 1996. 
  
x Two randomised controlled trials report that treatment with riluzole for up to 18 months 
significantly increases survival in ALS. In the first study, 58% of patients on placebo and 
74% on riluzole were alive at 12 months. In a second, larger, study, 50% of patients on 
placebo were alive at 18 months compared with 57% on riluzole 100 mg daily. Simple 
compararison of the survival in these trial groups shows no significant difference, 
although, after adjustment for prognostic factors, a modest improvement in survival is 
demonstrated. 
 
x The European Agency for the Evaluation of Medicinal Products (EMEA) in its conclusions 
in consideration of a marketing authorisation for Rilutek, (see Appendix A), said 
µWUHDWPHQWZLWKULOX]Rle does not demonstrate a positive effect on functional symptoms of 
the disease whilst the magnitude of the effect on survival is modest. There are therefore 
remaining uncertainties on the product in the management of Amyotrophic Lateral 
6FOHURVLV¶ 
  
x The lack of information regarding long-term survival benefits, caused by the short 
duration of the two studies, means that there is a level of uncertainty in the likely benefits 
achieved from the use of riluzole. An analysis of these uncertainties is presented in this 
report. Furthermore, it should be noted that there is some debate about the process of 
adjusting for prognostic factors used in the trial analysis. 
  
x The cost per life year gained over 18 months of treatment obtained from an unadjusted 
analysis of the trial data as published, is approximately £50,000, with a lower estimate of 
£22,000 and worst case of no benefit observed. When results are adjusted for prognostic 
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factors and modelled over a 10 year time horizon, under a range of different 
assumptions, the cost per life year gained is estimated to range between £14,800 and 
£41,000. The mid range estimate is £27,600 per life year gained. 
 
x The unadjusted trial data imply that it would be necessary to treat 11 patients for up to 18 
months to obtain one additional life year, that is the number needed to treat (NNT). Over 
the 10 year horizon the adjusted NNT ranges from two to seven. The central estimate is 
four. 
  
x Therefore, riluzole appears, at best, to offer modest clinical benefit in patients with ALS; it 
retards disease progression to a limited extent, but does not appear to arrest the disease 
and, on current evidence, it provides no other subjective or objective improvements. 
Quality of life studies have not been undertaken. Nevertheless, riluzole is an important 
step forward in the management of ALS. 
  
x The cost of treatment is about £3,700 per patient year. 
  
x The total annual cost for a typical district of 500,000 population of providing riluzole 
therapy to all ALS patients is approximately £99,000. This, however, represents a 
maximum as not all patients would be eligible for, or would request, treatment. 
  
x On current evidence, riluzole treatment should be limited to those patients most likely to 
benefit clinically, the selection of whom should be against agreed clinical criteria. The 
inclusion criteria of the clinical trials provide a baseline set of clinical criteria. However, 
further work should be undertaken to identify sub-groups of patients who would benefit 
significantly from treatment, either on the basis of a further analysis of the clinical trial 
data, or from other on-going primary research. Unpublished trial evidence indicates that 
no benefit is obtained from riluzole treatment in the population excluded from the trial 
under the exclusion criteria. 
  
x The uncertainty in long-term survival benefits means that mandatory monitoring of 
mortality and morbidity should be associated with treatment. 
x It is expected that treatment should normally be initiated on the advice of a consultant 
neurologist.  However, riluzole appears to be relatively safe, which makes the transfer of 
subsequent prescribing to GPs viable, depending on local policies and arrangements. 
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1. INTRODUCTION 
 
1.1 Motor Neurone Disease: Background to Disease 
 
Motor neurone disease (MND) is a progressive devastating neurological disorder involving 
motor neurones in the brain and spinal cord.1  About 5% of cases are familial. Several 
possible causes have been suggested including toxic activation of motor neurone glutamate 
receptors, excessive formation of free radicals and possible auto-immune mechanisms.  
There is no conclusive evidence to implicate any of these factors but, at present, glutamate 
related mechanisms appear to offer the most potential for research and treatment.  MND 
has classically been divided into three forms - progressive muscular atrophy, amyotrophic 
lateral sclerosis (ALS) and progressive bulbar palsy. ALS and progressive bulbar palsy are 
usually manifestations of the same illness but progressive muscular atrophy is a 
heterogeneous group, only a proportion of which is part of the ALS syndrome. 
 
1.2 Prognosis and Mortality 
 
ALS presents with a mixture of spasticity and muscle wasting.  It can begin in the bulbar or 
spinal muscles, although both eventually become involved as the disease progresses.  The 
bulbar form causes dysarthria and dysphagia resulting in loss of communication and 
nutritional problems. The spinal form presents with wasting and spasticity of one or more 
limbs, progressing with time. Respiratory muscles eventually become involved and a 
minority of patients present with respiratory failure. Intellectual deterioration is rare and 
involvement of ocular muscles and the bladder and bowel are unusual. 
 
Following presentation, the symptoms of ALS progress relentlessly. Conventional treatment 
is symptomatic and supportive and death commonly results from respiratory complications.  
Some patients are offered ventilatory support. 
 
The median survival from first symptoms in those with bulbar onset is about two years, with 
only 5% surviving five years. The median survival for those with spinal onset is about 2.5 
years, with nearly 15% surviving five years. 
 
1.3 Prevalence and Incidence 
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The prevalence of ALS is about 4-6 per 100,000 population, with an incidence of 1-1.5 per 
100,000 per year.2 Males are affected more often than females and incidence increases with 
age; onset of ALS usually occurs after 50 years of age.   
 
Based on current estimates of prevalence, there may be up to 280 people with ALS in the 
Trent region. In a typical district of 500,000 people, between five and eight new cases of 
MND would be expected per year. At any one time there would be between 20 and 30 
patients with MND. 
 
1.4 Riluzole and Motor Neurone Disease  
 
Riluzole ('Rilutek', Rhone-Poulenc Rorer) is a new drug which is believed to act by blocking 
the toxic effects of excessive glutamate on nerve cells. In 1994, Bensimon et al. published a 
trial of a new pharmaceutical treatment for MND, riluzole, which indicated that riluzole 
produced mortality and morbidity benefits.3 It has received marketing authorisation 
throughout the European Union through the centralised European Agency for the Evaluation 
of Medicinal Product (EMEA) / Committee for Proprietary Medicinal Products (CPMP) 
procedure, and in North America. It was launched in the UK in August 1996, and is indicated 
for use to extend life, or time to mechanical ventilation, in patients with ALS.  
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2.  USE OF RILUZOLE IN THE TREATMENT OF MOTOR NEURONE 
 DISEASE : SUMMARY OF EVIDENCE OF EFFECTIVENESS 
 
2.1 Summary of Evidence of Effectiveness of Riluzole 
 
Two major studies into the clinical effectiveness of riluzole in the treatment of MND have 
been published.3,4 These trials were undertaken by the same research group led by 
Lacomblez and Bensimon and both studies constituted prospective, randomised and 
double-blind placebo trials.  Details of these trials are summarised in Table 1. Both had 
similar entry criteria, including clinically probable or definite ALS of no greater than five 
\HDUV¶GXUDWLRQ IRUFHGYLWDOFDSDFLW\RIDW OHDVWRIWKDWSUHGLFWHGIRUSDWLHQWV
DJHDQG
height; and exclusion of patients with tracheostomy, renal dysfunction, and life threatening 
or incapacitating disease. The primary outcome measure was defined as tracheostomy-free 
survival during the double-blind period; end-points were death from any cause, 
tracheostomy, and intubation with artificial ventilation leading to tracheostomy. 
 
The first study randomised 155 patients into two groups, either bulbar-onset (n=32) or limb-
onset (n=123), which received riluzole 100 mg daily or placebo.3 Overall, 74% of riluzole 
patients were alive at 12 months, compared with 58% on placebo. In the bulbar-onset group  
73% were alive with riluzole compared with 35% on placebo and, in the limb-onset group, 
this figure was 74% compared with 64%. 
 
A second, larger, study looked at different doses of riluzole in 959 patients.4 Of 236 patients 
taking 100 mg riluzole daily, 57% were alive after 18 months, compared with 50% of 242 
taking placebo. Eighteen-month survival for patients taking 200 mg or 50 mg was 58% and 
55% respectively. Statistical analysis of the trial data, using a Cox Proportional Hazards 
Model to adjust for prognostic factors in the trial population, showed that 100 mg riluzole per 
day reduced the instantaneous hazard ratio at the 18 month timepoint by 35%, all other risk 
factors being equal (relative risk = 0.65, 95% Cl = 0.5-0.85, p=0.002 ). This cannot, 
however, be interpreted as a 35% reduction in 18 month mortality - any reduction that does 
occur through treatment would certainly be less than this. 
 
Bensimon et al. described a significant improvement in one year survival for bulbar-onset 
disease, with a non-significant effect on limb-onset ALS.3 The survival effect in the bulbar-
onset group was large enough such that the difference for those patients was seen in the 
entire trial population. Lacomblez et al. randomised patients by centre and by disease site-
  7 
onset as in the smaller study. They stated that outcomes were similar in patients with bulbar 
or limb-onset, although these data were not included in the results. Overall, a significant 
improvement in survival was shown. 
 
Both studies also looked at secondary outcomes: 
 
x Muscle strength assessed for 22 muscle groups with the patient in the sitting position, 
according to the Medical Research Council five-grade scale. 
x Functional status.  
x Respiratory function (vital capacity). 
x Patients' subjective assessment of fasciculations, cramps, stiffness, and tiredness.  
x Clinicians' global impression. 
 
No quality of life measurements were included. Overall, neither study showed significant 
improvement in secondary outcomes. However, the smaller study demonstrated significant 
improvement in muscle-testing scores (33% reduction in the rate of deterioration of muscle 
function). The second study showed no significant change in any secondary outcome 
measures. 
 
The absence of data showing beneficial effects of riluzole on quality of life or functionality is of 
concern. However, objective methods of evaluating motor function in ALS are relatively 
insensitive. Patients with ALS continue to deteriorate during treatment; the drug retards, but 
does not arrest, disease progression. It is perhaps unsurprising, therefore, that differences in 
functionality could not be demonstrated in the clinical trials. Further work in this area is under 
way. 
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Table 1: Summary of Clinical Trials 
 
TRIAL BENSIMON ET AL3 LACOMBLEZ ET AL4 
DESIGN Prospective, randomised, double-blind placebo 
controlled 
Prospective, randomised, double-blind, 
placebo controlled 
PATIENT NUMBERS 155 (32 bulbar, 123 spinal) 959 (295 bulbar, 664 spinal) 
INCLUSION CRITERIA age 20-75 
probable/definite ALS of no longer than 5 years, 
>60% predicted FVC* 
age 18-75  
probable/definite ALS of no longer than 5 
years, >60% predicted FVC* 
EXCLUSION CRITERIA Tracheostomy, renal dysfunction, other 
life-threatening or incapacitating disease 
Tracheostomy, renal dysfunction, other 
life-threatening or incapacitating disease 
PRIMARY END -POINT Death or tracheostomy at 12 months** Death or tracheostomy at 18 months** 
STUDY PERIOD 365 days 442-548 days 
DAILY DOSE 100 mg 50, 100, 200 mg 
OVERALL SURVIVAL 12 months 
Bulbar 
Spinal 
All 
Riluzole 
11/15(73%) [p=0.014] 
46/62(74%) [p=0.17] 
57/77(74%) [p=0.014] 
Placebo 
6/17(35%) 
9/61(64%) 
45/78(58%) 
Dose 
50mg 
100mg 
200mg 
All 
Placebo 
Survival  - 18 months 
131/237 (55%) 
134/236 (57%)  
141/244 (58%) 
406/717 (57%) 
122/242 (50%) 
INSTANTANEOUS 
RELATIVE RISK AT 12 
MONTHS  TIME-POINT 
OF TREATMENT OVER 
PLACEBO 
Dose 
 
100mg     0.43  (0.24 - 0.77)   [p=0.005] 
Dose       Unadjusted analysis - Table 3 
50mg      0.85  (0.66 - 1.11)   [p=0.25] 
100mg    0.79  (0.6 -  1.02)    [p=0.076] 
200mg    0.79  (0.61 - 1.03)   [p=0.075] 
All           0.81  (0.66 - 0.99)   [p=0.048] 
 
               Adjusted analysis - Table 4 
50mg      0.76  (0.59 - 0.99)   [p=0.04] 
100mg    0.65  (0.50 - 0.85)   [p=0.002] 
200mg    0.61  (0.47 - 0.80)   [p=0.0004] 
 
WITHDRAWAL DUE TO 
ADVERSE EVENTS 
27 on riluzole 
17 on placebo 
50 on placebo 
48 riluzole 50 mg 
54 riluzole 100 mg 
53 riluzole 200 mg 
 
* Forced Vital Capacity 
** Secondary end-points included limb and bulbar function, respiratory function, patients' subjective evaluations of cramps,  
fasciculations, stiffness, tiredness, clinicians' global impression. 
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2.2  Adverse Effects and Monitoring 
 
Adverse events were frequent in all study groups, for example, in the larger study 103/236 
(44%) patients treated with riluzole 100 mg reported respiratory system problems, compared 
with 115/242 (48%) patients on placebo. Many of the events are likely to be a direct result of 
ALS. Overall, riluzole was well tolerated in the clinical trials. However, a small, but important, 
number of patients had adverse events which could be directly attributable to treatment with 
riluzole. In particular, 85/717 (12%) had liver function test (LFT) disturbances, compared 
with 9/242 (4%) on placebo. Neutropenia was reported in three cases from phase III clinical 
trials. Clinical experience suggests that about 5% of patients withdraw from treatment 
because of adverse effects directly attributable to riluzole. The most common adverse 
reactions reported are asthenia, nausea and anorexia, which occur in 4-5% of patients, and 
abnormal LFTs.  Nausea and anorexia may respond to anti-emetics. 
 
Therefore, riluzole should be prescribed with care in patients with a history of abnormal liver 
function. Serum transaminases should be measured before starting treatment, monthly 
during the first three months, every three months in the remainder of the first year, and 
periodically thereafter. Transaminases should be monitored more frequently in patients who 
develop disturbances in liver function. Treatment should be stopped in patients whose ALT 
rises to five times the upper limit of normal. On present evidence, resumption of treatment is 
not recommended. In view of the reported cases of neutropenia, a full blood count should be 
performed regularly. 
 
2.3 Conclusion on Direction of Evidence and its Quality 
 
Riluzole treatment for up to 18 months has been shown to increase survival significantly in 
ALS.  Although it retards disease progression, riluzole does not appear to arrest the disease 
and, on current evidence, it provides no other objective or subjective improvement.  
Nevertheless, riluzole is an important step forward in the management of people with ALS, 
which has hitherto been supportive and palliative. 
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3. COST AND BENEFIT IMPLICATIONS OF ADOPTING INTERVENTION 
 
3.1 Analytical Overview 
 
Riluzole is the first treatment for MND to have shown mortality and morbidity benefits. These 
benefits have been identified in two published studies both undertaken by the same 
research group. As in all cases where there is such limited trial evidence there is significant 
uncertainty concerning the effectiveness of the treatment and, therefore, also in the related 
economic analysis. The two main sources of uncertainty in the economic analysis of riluzole 
are: 
 
x interpretation of the published RCT results for the 18 month period covered by the trial, 
specifically in terms of assessing the implications of prognostic factors on survival 
benefits; 
x long-term survival profiles beyond the 18 month period of the trial. 
 
The analysis presented here is based on the Lacomblez, Bensimon trial,4 the second and 
larger of the two published trials. The analysis focuses on the 100mg riluzole treatment 
group. The 50mg and 200mg treatment groups included in the RCT are not analysed here 
as these regimens are not licensed for use in the UK.  
 
The published statistical analysis of the trial4 includes adjustment for demographic and 
prognostic factors in the trial population. This adjustment has a marked effect on the 
benefits seen in the treatment group. The use of the hazard ratio, obtained from the Cox 
Proportional Hazards model, for demonstrating treatment effects means that the underlying 
baseline hazard, and thus baseline survival, are not evaluated. Further, insufficient 
information is given to quantify the baseline hazard and hence produce a complete survival 
analysis. Clearly, to assess the benefits in terms of survival, and hence life years gained, 
some measure of baseline survival is required. In this analysis a parametric baseline hazard 
function from the Weibull distribution has been assumed. This assumption cannot be tested 
without access to the raw trial data, thus there is a level of uncertainty in the adjusted 
outcomes. To address this issue an analysis based on the unadjusted trial results is first 
presented; this is followed by an analysis adjusted for prognostic factors. 
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The trial was stopped after 18 months, thus, there are no data available to evaluate the 
long-term effects of riluzole treatment. To address this issue a range of assumptions is 
considered for the long-term survival patterns beyond the 18 month trial period.  
 
The survival estimates and total costs are presented for a typical district population of 
500,000 under a range of prevalence and incidence rates. 
 
3.2 Cost-benefit Analysis Based on Trial Data with no Adjustment for 
Differences Between Prognostic Characteristics of Treatment Groups 
 
3.2.1 Unadjusted Survival Analysis for 18 Month Trial Period 
 
Table 2 and Figure 1 below give trial data and Kaplan-Meier tracheostomy-free survival 
estimates derived used an actuarial methodology. 
 
Table 2: Kaplan-Meier Survival Estimates for 18 Month Trial Period 
         
 AT  RISK 
(PERIOD    
 
START) 
DEATH OR TRACH. 
(Cum.) 
CENSORED (Cum.) SURVIVAL 
PROBABILITY 
MONTHS PLACEBO 100MG PLACEBO 100MG PLACEBO 100MG PLACEBO 100MG 
0 - 3 242 236  12  10   0  1 95% 96% 
3 - 6 230 225  37  28  1  1 85% 88% 
6 - 9 204 207  61  40  1  1 75% 83% 
9 - 12 180 195  90  62  1  1 63% 74% 
12 - 15 151 173 103  76 12 18 57% 67% 
15 - 18 127 142 120 102 81 83 47% 51% 
 
At 12 months the probability of tracheostomy-free survival  for the 100mg treatment group is 
74% compared to 63% for the placebo group; at 18 months the survival probabilities are 
51% and 47% respectively. 
 
Figure 1 shows the Kaplan-Meier step functions (---) obtained from the actuarial analysis of 
the published three monthly interval data, together with simple straight line interpolations 
between the interval end-points. The life years gained are calculated from the area between 
the interpolated placebo and 100mg survival plots. The average 100mg treatment cost per 
patient over 18 months is calculated from the area under the 100mg treatment survival 
curve (adjusted from months to years) multiplied by the cost per year of treatment.   
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Figure 1: Kaplan-Meier Tracheostomy-Free Survival Plots 
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Thus, over the 18 month trial period the 100mg treatment results in approximately 0.1 life 
years gained per patient, or just over 1 life month.  
 
The cost of riluzole is £286 per pack of 56 50mg tablets.5 The cost of drugs for one year of 
treatment on the 100mg per day dosage is approximately £3,720. The expected cost of 
drugs up to tracheostomy or death over an 18 month period is approximately £4,500.  
Therefore, if no adjustment is made for prognostic factors in the different patient groups, the 
cost per life year gained over the 18 month period is approximately £50,000.  
 
A range of estimates for the cost-effectiveness can be derived from the 95% confidence 
intervals for the Kaplan-Meier survival estimates of the treatment group and placebo group. 
It should be noted that, without adjusting for covariance between the two groups, this gives 
an overestimate of the variance of the benefit in terms of life years gained. However, with 
this proviso, it is important to note that the 95% confidence interval for life years gained 
includes no benefit. This is the corollary to the reported 95% confidence interval for the 
hazard ratio which includes a hazard ratio of 1, see Table 3 in the Lacomblez article.4 At the 
other end of the scale the 95% confidence limit results in a cost per life year gained of 
approximately £22,000. 
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The life years gained imply that it would be necessary to treat 11 patients for up to 18 
months to obtain one additional life year, that is the number needed to treat (NNT). The 
lower 95% confidence limit for the NNT is five, the higher limit is infinite where no benefit is 
obtained from treatment.  
 
3.2.2  Unadjusted Long-term Survival Analysis 
 
Another major area of uncertainty in the analysis is the lack of trial data beyond 18 months. 
A range of possible assumptions regarding the survival profiles over 18 months have been 
investigated in order to calculate the implications for the cost-effectiveness of riluzole. The 
analysis presented below is based on the actual trial estimates for the period 0 to 18 months 
together with three different assumptions regarding survival profiles beyond 18 months. 
 
Assumptions concerning the long-term survival for MND patients: 
 
A0 No treatment or placebo group: 
It is assumed that the hazard or risk of death is constant and independent of time 
since inclusion in the trial; the rate used is that indicated at the 18 month point in the 
trial for the placebo group. 
  
A1 100 mg treatment group - worst case: 
It is assumed that there is a sudden increase in death rate between 18 and 24 
months resulting in a return to placebo group survival levels at two years. Assuming 
that there are no toxic effects from long-term riluzole treatment, this is an absolute 
worst case assumption. 
 
A2 100 mg treatment group - mid-case: 
It is assumed that the hazard rate increases with time since inclusion in the trial after 
18 months.  (Note that this assumption implies that the hazard rate or risk of death 
after 18 months is greater in the treatment group than in the placebo group). 
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A3 100 mg treatment group - best case: 
It is assumed that the hazard rate is constant and independent of time since 
inclusion in the trial (that is a constant hazard rate), the rate used is that indicated at 
the 18 month point in the trial for the 100mg treatment group. 
 
The survival profiles implied by the above assumptions are given in Figure 2. 
 
Figure 2: Long-term Survival for Cohort of 30 Patients 
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The placebo treatment, assumption A0, is assumed to be associated with a constant age 
specific death rate. This assumption is supported by the proportional hazards model 
suggested by Haverkemp et al.6  and the exponential survival pattern suggested by Norris et 
al.7 Assumption A1, the worst case estimate, would require a sudden sharp increase in the 
death rate over the 18-24 month period. This assumption represents the worst case 
scenario, that the benefit from riluzole treatment is short-lived, and only suspends the 
progression of the disease during the first 18 month period; this would imply a very high 
death rate in the 18-24 month period. Assumption A2 represents a mid-case estimate where 
the hazard or risk of death in the treatment group increases after the 18 month period. This 
implies that benefits from riluzole treatment cease after 18 months and that survival 
deteriorates back to placebo levels after just over three years. Assumption A3 implies that 
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the constant age-specific rate of death indicated at the 18 month period is maintained 
throughout the rest of the natural progression of the disease. This is not strictly a best case 
since it assumes that there are no long-term benefits arising from the cumulative effect of 
drug therapy and also that no long-term delay in disease progression results from therapy. 
Thus, it may be argued that this is a conservative best case assumption. 
 
The following tables give the resultant expected survival and costs profiled over a 10 year 
horizon for an original cohort of 30 patients under placebo treatment, A0, and under the 
100mg treatment with the three long-term survival assumptions A1, A2 and A3. 
 
Table 3: Unadjusted Survival within the Cohort 
 
YEAR PLACEBO A1 A2 A3 
0 30.0 30.0 30.0 30.0 
1.5 14.0 15.4 15.4 15.4 
3   6.5   6.5   7.2   7.9 
5   2.4   2.4   2.5   3.3 
10   0.2   0.2   0.2   0.4 
     
 
Table 4: Unadjusted Life Years Gained and Total Cost 
 
 CUMULATIVE LIFE YEARS GAINED TOTAL COST (Cum.)  
YEAR A1 A2 A3 A1 A2 A3  
1.5 2.7 2.7 2.7 £134,800 £134,800 £134,800  
3 3.1 4.3 4.9 £191,000 £195,500 £197,800  
5 3.1 5.0 7.2 £221,500 £228,600 £237,000  
10 3.1 5.0 9.5 £237,400 £244,700 £261,400  
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Table 5: Unadjusted Cost per Life Year Gained 
 
YEAR A1 A2 A3  
1.5 £50,000 £50,000 £50,000  
3 £62,500 £45,700 £40,400  
5 £72,500 £46,000 £32,800  
10 £77,700 £48,900 £27,500  
     
 
Table 6: Unadjusted Number Needed to Treat 
 
YEAR A1 A2 A3 
1.5 11.1 11.1 11.1 
3   9.8   7.0   6.1 
5   9.8   6.0   4.2 
10 
  9.8   6.0   3.2 
 
 
Under the worst case scenario, assumption A1, no life years benefit is obtained after 
eighteen months, however, the cost of riluzole treatment still accrues over the 10 year time 
horizon, leading to a very high cost per life year gained. Under the mid-range assumption 
A2, even though no positive benefit is obtained from riluzole after 18 months, the slower 
return to placebo survival levels means that the cost per life year gained is stable at around 
£50,000. Assumption A3 assumes that the benefits from riluzole are maintained and result 
in a cost per life year gained over the 10 year period of £27,500. 
 
3.3 Cost-benefit Analysis Based on Trial Results Adjusted for Differences 
between Prognostic Characteristics of Treatment Groups 
 
3.3.1 Adjusted Survival Analysis for 18 Month Trial Period 
 
The published trial analysis identifies 10 demographic and clinical baseline variables as 
independent prognostic factors in disease progression. The placebo and 100mg treatment 
groups were not randomised over these 10 factors and hence adjustment is necessary to 
account for the different population characteristics in each group. 
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A Cox Proportional Hazards Model is used to undertake this adjustment. A review of this 
model and the implementation described in the published paper is included in Appendix B.  
To summarise, the hazard at any point in time for an individual is defined as the risk of dying 
in a very short time interval given that the individual has survived to the start of that interval. 
The basis of the Cox Proportional Hazards model is that the hazard or risk at any point in 
time is assumed to be proportional to each of the prognostic factors. The Cox model is a 
semi-parametric model and makes no assumption about the underlying survival 
characteristics of the population. Thus, whilst the model allows comparisons to be made 
between treatment groups no absolute measure of survival is obtained.  
 
In order to obtain an absolute estimate of the survival adjusted for prognostic factors from 
the information provided in the published paper, it is necessary to make an assumption 
regarding the form of the baseline hazard:  
 
A4 In order to estimate the survival in the placebo and treatment groups from the hazard  
information presented in the published paper, the analysis presented here assumes 
a Weibull baseline hazard function. 
 
Figure 3 shows the empirical survival plots, against a Cox Proportional Hazards Model with 
baseline hazard function from the Weibull distribution. The model is based on the treatment 
group profiles as detailed in Table 1 of the published article and the prognostic scores given 
in Table 4 of the article. The parameters of the baseline function are estimated by 
minimising the least squares difference between the model estimates at three monthly 
intervals and the interval estimates from the actuarial analysis described in Section 3.2.1.  
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Figure 3: Empirical Survival Plots and Best Fitted Survival from Cox 
Proportional Hazards Model with Weibull Baseline Hazard 
Function 
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The survival for the placebo and 100mg treatment groups is then adjusted to the estimated 
survival for a population with the same characteristics as the total trial population. 
  
It should be emphasised that these adjustments are made to account for differences 
between treatment groups within the trial. Furthermore, if the ALS population in a district has 
markedly different characteristics from the trial population then further adjustments may be 
appropriate in assessing the implications of riluzole use in that population. 
 
The life years gained and the drug treatment costs are calculated as in Section 3.2.1. The 
expected cost per life year gained over the 18 month period after adjustment for prognostic 
factors falls to £39,000. It would be necessary to treat approximately nine patients for up to 
18 months in order to achieve one life year benefit. 
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3.3.2 Long-Term Survival Analysis Adjusted for Prognostic Factors 
 
A similar set of assumptions regarding long-term survival patterns are explored for the 
adjusted analysis. Figure 4 presents the survival profiles under the three assumptions 
considered. 
 
Figure 4: Adjusted Long-term Survival for Cohort of 30 Patients 
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Table 7: Adjusted Survival in the Cohort 
 
YEAR PLACEBO A1 A2 A3 
0 30.0 30.0 30.0 30.0 
1.5 13.1 17.5 17.5 17.5 
3   2.9   2.9   3.4   6.6 
5   0.2   0.2   0.2   1.2 
10   0.0   0.0   0.0   0.0 
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Table 8: Adjusted Life Years Gained and Total Costs 
 
YEAR A1 A2 A3 A1 A2 A3 
1.5 3.5 3.5   3.5 £136,200 £136,200 £136,200 
3 4.6 7.1 10.1 £180,100 £189,400 £200,500 
5 4.6 7.2 14.4 £188,400 £198,100 £225,000 
10 4.6 7.2 15.5 £188,900 £198,600 £229,300 
 
Table 9: Adjusted Cost per Life Year Gained 
 
YEAR A1 A2 A3 
1.5 £39,000 £39,000 £39,000 
3 £39,200 £26,800 £19,900 
5 £41,000 £27,500 £15,600 
10 £41,100 £27,600 £14,800 
 
Table 10: Adjusted Number Needed to Treat 
 
YEAR A1 A2 A3 
1.5 8.6 8.6 8.6 
3 6.5 4.2 3.0 
5 6.5 4.2 2.1 
10 6.5 4.2 1.9 
 
 
The large decrease in cost per life year gained and in NNT between 18 months and the 10 
year time horizon emphasises the importance of long-term survival patterns in the cost-
effectiveness of riluzole. This highlights the need to undertake long-term monitoring of 
patient survival if riluzole treatment is undertaken. 
 
The estimates of cost per life year gained, under the assumptions presented in this report, 
range between £14,800 under the best case assumption of maintained benefits from riluzole 
to £41,000 under the worst case assumption. The mid-range estimate is £27,600 per life 
year gained.  
 
The estimate of the adjusted number NNN is four and ranges from two to seven. 
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Using the Treasury discount rate of 6% to discount both costs and benefits the discounted 
cost per life year gained figure is £28,200.  This increase reflects the fact that the majority of 
the costs are incurred in the early years whilst the majority of the life years benefits are 
achieved later in treatment. 
 
Table 11 below gives the total costs per annum associated with 100mg riluzole treatment for 
a district population of 500,000. These costs assume that the entire MND prevalence 
population uses riluzole treatment irrespective of the time since onset of disease, age or 
contra-indicating factors. In addition, a proportion of patients may not take up treatment due 
to the lack of proven functional or quality of life benefit. Therefore, these figures are likely to 
be overestimates; a simple proportionate adjustment for the appropriate total prevalence 
treated would give the associated expected costs. 
 
Table 11: Total Cost per Annum of Riluzole in a District of 500,000  
  Population 
 
PREVALENCE (PER 500,000 pop.) DRUG COSTS 
20 £66,000 
30 £99,000 
40 £132,000 
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4. OPTIONS FOR PURCHASERS AND PROVIDERS 
 
Empirical analysis of the 18 month trial data indicates a high cost per life year gained over 
18 months for the trial population. However, uncertainty regarding the implications of 
prognostic factors on survival and uncertainty regarding long-term treatment benefits due to 
the short duration of the study imply that the long-term cost-effectiveness is likely to be 
underestimated. In the light of this uncertainty the three options for purchasers are : 
 
Option 1: Do Not Fund the Purchasing of Riluzole. 
  
 The published trial demonstrates a reduction in risk of death through the use of riluzole 
WKHUHIRUHGHVSLWHWKH(0($¶VUHVHUYDWLRQVRQWKHXVHRIULOX]ROHVHH$SSHQGL[$HWKLFDO
arguments may prevent further large scale, long-term clinical trials. Therefore a decision not 
to fund the provision of riluzole would have to be based on the expectation that further 
analysis of the trial data would clarify the effects of prognostic and demographic factors on 
survival and that the experience of other purchasing bodies would clarify the long-term 
survival patterns associated with riluzole use. 
  
 Option 2: Limited Funding of Riluzole 
  
 Make riluzole available to patients who satisfy strict clinical criteria and institute mandatory 
monitoring of long-term patient survival. 
  
 The inclusion criteria for the two studies should be used as initial baseline selection criteria; 
these are detailed further in the following discussion. Further scope exists to identify specific 
patient sub-groups which would benefit from riluzole treatment. Firstly, a further analysis of 
the trial data could investigate the benefits achieved in the high and low risk groups 
identified in the Lacomblez article, (see Figure 2 of that paper).4 Secondly, a small scale 
study by Sojka8  has identified evidence that riluzole may not be uniformly effective for all 
W\SHV RI $/6 DQG FRQFOXGHV µZKHWKHU WKHUH H[LVW VXEJURXSs of ALS patients especially 
VXLWHGWRULOX]ROHWUHDWPHQWPXVWEHVHWWOHGLQIXUWKHUVWXGLHV¶ 
  
Further work would be required to define a protocol for the mandatory monitoring of long-
term survival. Due to the low incidence of ALS, monitoring of survival should be co-ordinated 
over a group of purchasing bodies. The trial results did not indicate a significant effect on 
functional outcomes. This, together with the low sensitivity of the available functional 
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outcome measures, implies that such monitoring should focus on mortality or tracheostomy-
free survival rather than ALS associated morbidity. Historical survival data, where available, 
together with the published reviews of long-term survival6,7,9,10,11 should be used to identify a 
null treatment survival baseline. Alternatively, a methodology such as that used by Sojka8 
may provide the ability to monitor effects of riluzole on the disease progression rate of 
individuals.  
  
 In addition, purchasing bodies should seek further clarification on the effects of prognostic 
factors in determining survival benefits; validation of the assumptions made in the analyses 
presented here would mean that the cost-effectiveness of riluzole treatment would be in line 
with other funded interventions. 
  
 Option 3: Fund Unrestricted Riluzole Use. 
  
 The effectiveness of riluzole in extending tracheostomy-free survival has only been identified 
in the sub-group of people with ALS which satisfied the inclusion criteria for the trial. 
Benefits in terms of reduced risk of death or tracheostomy have not been proven in the 
population excluded from the analysis. Furthermore, a double blind placebo controlled study 
of the use of riluzole in ALS patients who did not fulfil the inclusion criteria for the study was 
undertaken in parallel to the main Lacomblez study.4 This study was undertaken on 
compassionate grounds. The results from this study are unpublished but identify no 
significant benefit in terms of tracheostomy-free survival arising from the use of 100mg 
riluzole in this high risk population. 
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5. DISCUSSION AND CONCLUSION 
 
A review of the statistical analysis presented in the Lacomblez article4 has been undertaken 
and is presented in Appendix B. This review supports the validity and appropriateness of 
that analysis and the claims made for a statistical evidence of dose response relationship 
between riluzole use and tracheostomy-free survival. 
 
There are, however, considerable difficulties in interpreting the results in a manner which is 
meaningful when considering the clinical usefulness of treatment and hence when 
considering whether or not to support the purchase of riluzole. Bensimon in his reply to 
Guiloff13 recognises that it is preferable to consider the absolute decrease in event rate 
rather than the relative risks at a point in time, however, such figures are not provided for 
the trial results adjusted for prognostic factors. This shortcoming in the paper is 
compounded by the fact that the published articles are not clear in the description of results, 
for example, Table 3 of the Lacomblez article4 and Table IV of the Bryson article12 refer to 
survival analysis when the statistics presented are the relative risks (or relative hazards) at 
the 12 and 18 month time-points. Further, an improvement in median survival of three 
months has been quoted and attributed to the Bensimon, Lacomblez studies. This claim is 
not made in the Lacomblez article4 and is refuted by Bensimon in his reply to the letter by 
Guiloff.13 Further, since the survival in the 100mg treatment group does not drop to 50% and 
the placebo group only reaches 50% at the extreme end of the study, it is not possible to 
measure the improvement in terms of median survival. 
 
The analysis presented in this report attempts to interpret the published results in a manner 
which is meaningful for purchasers. This is undertaken through modelling of long-term 
survival patterns under a range of different assumptions, together with Cox Proportional 
Hazards modelling of the trial data. It should be noted that some of the published effects of 
prognostic factors appear to be counter intuitive. For example visual analogue scale (VAS) 
stiffness and disease duration appear to decrease risk. The disease duration effect could 
imply that progressive ALS is a heterogeneous group. That is, individuals who have 
progressed quickly from onset to diagnosis and subsequent inclusion in the trial are more 
likely to have a rapidly progressing disease, whilst individuals who have a slowly progressing 
disease are more likely to have a high disease duration at inclusion in the trial. Guiloff13 
quite rightly expresses caution when interpreting such proportional hazards models. 
This caution should be redoubled in the light of the long-term survival modelling made 
necessary by the short duration of the trials. It could be argued that Rhone-Poulenc Rorer 
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were unethical in allowing the trial to stop before incontrovertible evidence concerning the 
GUXJ¶V XVH RYHU WKH W\SLFDO OLIHVSDQ RI WKH GLVHDVH ZDV REWDLQHG 7KLV WRJHWKHU ZLWK WKH
OLFHQVLQJERGLHV¶ZLOOLQJQHVVWRDSSURYHWKHGUXJZKLOVWXQFHUWDLQWLHVLQLWVXVHVWLOOH[LVWKDV
put local health authorities in the position of having to make purchasing decisions on 
minimal information. The intention here has not been to produce an analysis by haphazardly 
throwing caution to the wind, but rather to extend the published analyses to be able to say 
something about the likely cost-effectiveness of riluzole given a set of clearly identified 
assumptions, and hence to support purchasing decision makers. The analysis aims to 
highlight the potential long-term cost-effectiveness of riluzole, the need for further 
information from the trial study and the need for further information on long-term survival. 
 
However, the best estimate of cost per life year gained, that is £27,600, is higher than that 
for many healWKFDUH LQWHUYHQWLRQV FXUUHQWO\ LQ XVH IRU H[DPSOH WKH XVH RI ³VWDWLQV´ LQ WKH
secondary prevention of coronary heart disease has a cost per life year gained of £5,100. 
Haemodialysis for end-stage renal failure, which is widely recognised as a high cost 
intervention, is more cost effective at around £20,000 per life year gained.  
 
Riluzole treatment for up to 18 months has been shown significantly to increase survival in 
ALS.  Further, since the study4 appears to be based on a mixed prevalence and incidence 
population, intuitively one might expect that patients prescribed the drug as they present may 
derive more benefit than a cohort which would include by definition patients who have 
progressed markedly with the disease. The manufacturer states that newly or recently 
diagnosed patients, with more functioning motor neurones available when treatment is 
initiated, are more likely to benefit from riluzole. Moreover, in an unpublished study of late 
stage ALS, survival time with riluzole treatment did not differ from placebo.  However, 
although riluzole retards disease progression, it does not appear to arrest the disease and, 
on current evidence, provides no other objective or subjective improvement. Nevertheless, 
riluzole is an important step forward in the management of people with ALS, which has 
hitherto been supportive and palliative. It is currently licensed to extend life or the time to 
mechanical ventilation in these patients. 
 
It is recommended, therefore, that limited funding is provided for riluzole together with 
mandatory monitoring. This recommendation is made in the light of the above comments 
and bearing in mind specifically the inclusion criteria used in the clinical trials and research 
being undertaken to identify patient sub-groups for treatment. The following criteria should 
normally be met before offering patients treatment with riluzole: 
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x A diagnosis of definite or probable ALS made by a consultant neurologist; 
  
x The contra-LQGLFDWLRQV DQG SUHFDXWLRQV VSHFLILHG LQ WKH µ6XPmary of Product 
Characteristics,14 should apply: 
(a) Patients who have a history of severe hypersensitivity reactions to riluzole or any of 
the tablet components 
(b) Patients who have hepatic disease or who have baseline transaminases greater than 
three times the upper limit of normal 
(c) Patients who are pregnant or lactating.  
  
x Treatment should be initiated by a consultant neurologist and only after a frank discussion 
with the patient; 
  
x Blood tests should be performed monthly for the first three months and, thereafter, every 
three months to monitor for adverse hepatic effects. 
 
There is no upper age limit for riluzole treatment. Patients in the clinical trials had mean 
ages in the range 50-60 years, and the oldest patient was 75 years of age. Patients should 
be in a reasonable state of general health without features of dementia, renal or hepatic 
dysfunction. It has been suggested that respiratory function should normally show forced 
YLWDOFDSDFLW\)9&QRWOHVVWKDQRIWKDWSUHGLFWHGIRUWKHSDWLHQW¶VDJHDQGKHLJht for 
treatment to be considered.  
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6. USE OF RILUZOLE IN THE TREATMENT OF MOTOR NEURONE DISEASE : SUMMARY MATRIX 
 
T PATIENT GROUP PATIENT CRITERIA 
(GUIDELINES NOT 
PROTOCOLS) 
ESTIMATED 
FUTURE 
ACTIVITY 
OPPORTUNITY 
FOR COST SAVING 
AUDIT POINTS EFFECTS THAT 
COULD BE 
EXPECTED IN 
RELATION TO 
STARTING POINT 
 
COST-EFFECTIVENESS 
Patients with 
ALS/MND. 
 
 
 
 
 
 
 
 
 
Patients aged 17-75 with clinically 
probable or diagnosed ALS. 
Disease duration no longer than 5 
years. 
Predicted FVC >60%. 
Prevalence 
estimate for all 
MND is 30 for a 
district population 
of 500,000.    
 
Annual incidence 
ranges from 5 - 8 
patients.  
No comparable 
treatment. 
 
Impact upon use of 
other health and 
social services 
unknown.  
Mandatory long- 
term monitoring 
of tracheostomy-
free survival 
should be 
undertaken. 
Reduced mortality The best current estimate 
of long-term cost-
effectiveness ranges from 
£14,800 to £41,100 with a 
central estimate of £27,600. 
 
The number needed to treat 
over 18 months is 
approximately 9.  
Over a 10 year treatment 
horizon  the estimate 
ranges from 2 - 7 with a 
central estimate of four. 
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APPENDIX A: CONCLUSIONS OF THE COMMITTEE FOR PROPRIETARY
 MEDICINAL PRODUCTS (CPMP) OF THE EUROPEAN AGENCY
 FOR THE EVALUATION OF MEDICINAL PRODUCTS (EMEA) IN
 CONSIDERATION OF A MARKETING AUTHORISATION FOR
 RILUTEK. (CPMP/132/96 - Procedure No. EMEA/H/C/109/00/00) 
 
(Extract from &RPPLWWHH IRU3URSULHWDU\0HGLFLQDO3URGXFW¶V(XURSHDQ3XEOLF$VVHVVPHQW
Report (EPAR) on Rilutek (CPMP/290/96) : International Non-Proprietary Name (INN): 
Riluzole. European Agency for the Evaluation of Medicinal Products. 1996                        
< http://www.eudra.org/emea.html>(9.10.1997)) * 
 
Riluzole has been demonstrated to extend survival in two studies conducted in patients with 
ALS, but not in a third trial. Survival was the main efficacy criterion and was considered as a 
strong outcome measure. 
 
The failure to find any effect on functional end-points does not affect the reliability of the 
survival results. 
 
The survival data obtained with riluzole were analysed at several time-points to explore the 
robustness of the findings: the general consistency of the findings is of interest, rather than 
specific achievements of selected significance levels. The consistent outcome of 
significance levels achieved in the different analyses, together with the higher levels of 
statistical significance associated with the Cox model, is reassuring. 
 
An effect on functional end-points, if established, would help to support the survival results: 
however, up to date scores on functional scales are not validated as surrogate markers of 
survival in ALS. 
 
The CPMP in its meeting on 14 February 1996 adopted by scientific consensus a positive 
opinion on Rilutek. 
 
The Committee in recommending the granting of a marketing authorisation felt it was 
LPSRUWDQW WR VHW RXW LQ WKH µ6XPPDU\RI3URGXFW&KDUDFWHULVWLFV¶ WKH UHVXOWVRI WKH FOLQLFDO
trials on which the authorisation was based. The Committee felt that this was particularly 
important because treatment with riluzole does not demonstrate a positive effect on 
functional symptoms of the disease whilst the magnitude of the effect on survival is 
modest. There are therefore remaining uncertainties on the product in the 
management of Amyotrophic Lateral Sclerosis. 
The specialist physicians using riluzole will be fully aware of the data. 
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The therapeutic indication approved is the following: 
 
³5LOX]ROH LV LQGLFDWHG WR H[WHQG OLIH RU WKH WLPH WR PHFKDQLFDO YHQWLODWLRQ IRU SDWLHQWV ZLWK
amyotrophic lateral sclerosis (ALS). 
 
Clinical trials have demonstrated that RILUTEK extends survival for patients with ALS. 
 
Survival was defined as patients who were alive, not intubated for mechanical ventilation 
and tracheotomy-free. 
 
There is no evidence that riluzole exerts a therapeutic effect on motor function, lung 
function, fasciculations, muscle strength and motor symptoms. Riluzole has not been shown 
to be effective in the late stages of ALS. 
 
Safety and efficacy of riluzole has only been studied in ALS. Therefore, riluzole should not 
EHXVHGLQDQ\RWKHUIRUPRIPRWRUQHXURQHGLVHDVH´ 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________ 
* Reproduction authorised by the EMEA.  Copyright EMEA 1997 - Reproduction by third party is 
authorised, except for commercial purposes, provided the knowledge source is acknowledged. 
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APPENDIX B:  ScHARR  INTERNAL REVIEW OF STATISTICAL ANALYSIS  
   35(6(17(' ,1 µ'26(-RANGING STUDY OF RILUZOLE              
   ,1$0<27523+,&/$7(5$/6&/(526,6¶Lancet 1996; 347:  
   1425-31. 
 
Comments on Article 
Lacomblez L, Bensimon G, Leigh PN, Guillet P and Meininger V. Dose-ranging study of 
riluzole in amyotrophic lateral sclerosis. Lancet 1996; 347: 1425-31. 
 
7KHµ8QDGMXVWHG$QDO\VLV¶ 
 
The logrank test is a non-parametric method for testing the null hypothesis that the groups 
being compared are samples from the sample population as regards survival experience. 
The principle of the logrank test is to divide the survival time scale into intervals according to 
the distinct observed survival times, ignoring censored survival times. For each time period 
we compare the observed data (O) with what we would expect (E) if the null hypothesis that 
there is no real difference between the groups is true. 
 
The logrank test to compare k groups produces for each group an observed (O) and 
expected (E) number of events. These are compared by calculating the sum of (O-E)2/E, 
called X2, and comparing this result to a F2 distribution with k - 1 degrees of freedom. 
 
The logrank test can be extended to allow an adjustment to be made for other variables. In 
this paper the subjects are divided or stratified into sub-groups according to the site of 
disease onset. The values of O and E are calculated for each treatment group within each 
stratum. For each treatment group the values of O and E from each stratum are added up 
and then these sums are compared using the usual logrank formula to get X2. 
 
7KHµ$GMXVWHG$QDO\VLV¶0RGHOOLQJ6XUYLYDO- the Cox Regression Model 
 
The logrank test is a non-parametric method for comparing the survival experience of two or 
more groups. It cannot be used to explore (and adjust for) the effects of several variables 
(such as age, disease duration, bulbar sign at entry etc.) on survival - for this we need a 
regression method. 
 
&R[¶V3URSRUWLRQDO+D]DUGVUHJUHVVLRQDQDO\VLVLVDµVHPL-SDUDPHWULFDSSURDFK¶1R
particular type of distribution is assumed for the survival times, but a strong assumption is 
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made that the effects of different variables on survival are constant over time and are 
additive in a particular scale (Altman, 1991). 
 
The hazard function represents the risk of dying in a very short time interval after a given 
time, assuming survival thus far. It can be interpreted, therefore, as the risk of dying at time 
t&R[¶VPHWKRG LVVLPLODU WRPXOWLSOHUHJUHVVLRQDQDO\VLVH[FHSWWKHGHSHQGHQWYDULDEOH LV
the hazard at a given time. If we have several variables of interest (e.g. age, disease 
duration, bulbar signs at entry etc.), we can express the hazard or risk of dying at time t as: 
 
h(t) = h0(t) x exp(bage.age + bduration duration + ... + bN.America N.America). 
 
The quantity h0(t)  is the baseline or underlying hazard function and corresponds to the 
hazard when all the variables are zero (because e0 = 1). The regression coefficients bage to 
bN.America  are estimated using the method of maximum likelihood (Collett, 1994) using an 
appropriate computer program (e.g. SAS or SPSS). 
 
If we have just one variable of interest, e.g. age then: h(t) = h0(t) x exp(bage x age). Under 
this model a proportionate change in age such as a 50% increase from 40 to 60 years, 
results in a proportional change in the log of the hazard. This is the reason for the name 
µSURSRUWLRQDO KD]DUGV¶ DQG WKH IDFW WKDW IRU WZR FDVHV WKH UDWLR RI WKH KD]DUGV ZLOO EH D
constant for all time-points. 
 
The assumption of proportional hazards can and should be tested. This appears to have 
been carried out in the study, (page 1427, second column, 1st paragraph) although the 
results are not reported.   
 
The Cox model must be fitted using an appropriate computer program although no name is 
given in the paper. This program does appear to allow for the stepwise selection of 
prognostic variables. An appropriate stepwise selection procedure with a significance level 
of 5% for variable entry in the model appears to have been used.  
 
The value of the riluzole dose ranges from 0 mg (placebo) to 200 mg. In order to guard 
against the extreme values of this variate having an undue impact on the coefficient of dose, 
natural logarithms have been used in the modelling process. So the riluzole doses (of 50 
mg, 100 mg and 200 mg) were transformed by the use of the natural log transformation. 
E.g. ln(placebo) = 1, ln(50) = 3.9; ln (100) = 4.6; ln(200) = 5.3.  
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The possibility of interactions between the treatment effect and site of onset and countries 
appears to have been investigated in the study, (page 1427, second column, 1st paragraph) 
although again the results are not reported.   
 
Interpretation of Model 
 
The final model from a Cox regression analysis will yield an equation for the hazard as a 
function of several covariates (11 plus treatment variables in this paper- see Table 4). The 
coefficients of the explanatory variables in the model can be interpreted as logarithms of the 
ratio of the hazard of death to the baseline hazard.  
 
For continuous covariates (e.g. age, disease duration, weight etc.) the regression coefficient 
refers to the increase in log hazard for an increase of 1 in the value of the covariate. Thus at 
18 months (page 1428, Table 4) the estimated hazard or risk of death increases 1.48 times 
if a patient is 10 years older, after adjustment for the effects of the other variables in the 
model.  
 
The above interpretation, assumes that the hazard ratio for an individual aged 70, relative to 
one aged 60, would be the same as that for an individual aged 30 relative to one aged 20 
other things being equal. This linearity assumption can be checked by fitting a factor to the 
model with levels corresponding to different age bands. There is no written evidence to 
suggest this has been carried out except for the variate drug dose. However, this does not 
seem to affect the overall statistical validity of the model. 
 
Similarly, the effect off 50 mg of riluzole is to reduce the hazard to 0.76 of that of the 
placebo. The overall effect on the survival probability, however, cannot be described simply 
DVLWGHSHQGVRQWKHSDWLHQW¶VYDOXHVRIWKHRWKHUYDULDEOHVLQWKHPRGHO 
 
 
 
 
Prognostic Index 
 
The combination of the regression coefficients and values of variables can be used as a 
prognostic index (PS) or score (page 1428, second column, 1st paragraph).  
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E.g. PS = (ln 1.48 x age) + (ln 0.67 x disease duration) + ... + (ln 0.69 x N.America). 
 
After calculating the PS for all 959 patients, the trial population was split by its median PS 
into two groups (high and low risks) and Kaplan-Meier survival plots produced for these two 
new groups (page 1428, Figure 2). Unfortunately, no mention is given of what this median 
group splitting value was. This omission makes it difficult to estimate the probability of a new 
patient surviving a given time. 
 
Summary 
 
Overall the article is well written and the appropriate statistical methods have been used. 
The use of riluzole in this group of amyotrophic lateral sclerosis (ALS) patients has led to an 
increase in survival without a tracheostomy even after adjustment for prognostic factors. 
There is strong statistical evidence of a dose-response relationship between the use riluzole 
and tracheostomy-free survival in this group of patients i.e. increased doses of riluzole lead 
to longer tracheostomy-free survival. 
 
If this study population is representative of ALS patients, then there is clear evidence that 
larger doses of riluzole will lead to longer survival. No details are available on the optimum 
dose for individual ALS patients, although a prognostic scoring index could be calculated for 
an individual ALS patient which might aid clinical decision making. Finally no information is 
DYDLODEOHRQWKHµFKDQJH¶LQTXDOLW\RIOLIHRIWKH$/6SDWLHQWVJLYHQWKHLULQFreased survival. 
Are we adding life to their years or years to their life? 
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